Key Highlights
- Abbott Laboratories (NYSE:ABT) reported third-quarter sales of USD 13.01 billion on Wednesday, October 21, 2026, up 14.5% reported and 7.0% on a comparable basis, with adjusted EPS of USD 1.42 against USD 1.30.
- The company reaffirmed the midpoint of its 2026 adjusted EPS guidance and tightened the range to USD 5.50 to USD 5.55, with comparable sales growth of about 6.0% for the year.
- Diabetes Care sales rose 6.7% on a comparable basis to USD 2.19 billion, with continuous glucose monitor sales up 7.7%, and Dexcom (NASDAQ:DXCM) fell about 6% to 6.5%.
- Readings of the outlook differ: the EPS midpoint was reaffirmed, while press reports described the full-year growth guidance as trimmed, and Abbott shares fell on the day.
A Beat With a Narrower Range
Abbott Laboratories (NYSE:ABT), a diversified healthcare group spanning medical devices, diagnostics, nutrition and branded generic drugs, reported third-quarter results on Wednesday, October 21, 2026. Sales were USD 13.01 billion, up 14.5% from USD 11.37 billion, or 7.0% on a comparable basis. Adjusted EPS rose 9.2% to USD 1.42, while GAAP EPS fell to USD 0.53 from USD 0.94. Medical Devices sales rose 7.8% comparable to USD 5.83 billion, and Diagnostics reached USD 3.31 billion, up 46.7% reported after the acquisition of Exact Sciences, completed on Monday, March 23, 2026. Abbott tightened 2026 adjusted EPS guidance to USD 5.50 to USD 5.55, reaffirming the midpoint. It guided fourth-quarter adjusted EPS to USD 1.62 to USD 1.67. Abbott also announced plans to separate its Nutrition business.
Why a Reaffirmed Midpoint Still Weighed on the Shares
For Abbott Laboratories (NYSE:ABT), the tension sits between earnings and growth. The EPS midpoint held, but the comparable sales growth outlook of about 6.0% sits below the 7.0% delivered in the quarter, and press reports read it as a trimmed growth outlook. The gap between 14.5% reported and 7.0% comparable growth comes mainly from Exact Sciences, which is included in both years of the comparable measure. Diabetes Care, home to the FreeStyle Libre glucose sensors, grew 6.7%, with monitor sales up 7.7%. For a category that investors value mainly on growth, a pace below 8% can pressure valuation multiples across the group. The read-through explains why Dexcom, the other large monitor maker, fell about 6% to 6.5% on a day when the S&P 500 rose 0.58%.
Risks and What to Watch
The first risk for Abbott Laboratories (NYSE:ABT) is that continuous glucose monitor growth near 7.7% marks a durable slowdown rather than a single quarter, which would weigh on the segment investors value most. The second is execution on the Nutrition separation, which can bring stranded costs, meaning overheads left behind once a unit leaves. The third is integration of Exact Sciences, which now inflates reported growth and must deliver its cancer screening targets. Higher rates also weigh on long-duration healthcare valuations. Investors should watch the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026, further detail on the Nutrition spin-off and fourth-quarter EPS against the USD 1.62 to USD 1.67 guide.
Where Things Stand
The answer is that both readings hold: Abbott Laboratories (NYSE:ABT) reaffirmed its EPS midpoint and narrowed the range to USD 5.50 to USD 5.55, while its roughly 6.0% sales growth outlook was widely read as a trim. Diabetes Care growth of 6.7% carried the larger signal, hitting Dexcom as well. The next catalysts are the Fed decision on October 28, the midterm elections on November 3 and Nutrition spin-off terms. Guidance is a company forecast, not a guarantee, and this is not investment advice.






Please wait processing your request...